EMGALITY™ (galcanezumab) now available in Canada for preventive treatment of migraine

Wednesday, October 2, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

_______________________

1 Emgality Product Monograph. July 30, 2019

2 The International Classification of Headache Disorders, 3rd edition. (2018). Cephalalgia, 38(1), 1-211

3 Ramage-Morin, PL and Gilmour H, Prevalence of migraine in the Canadian household population, Health Reports, Vol. 25, no. 6, pp.10-16, June 2014, Statistics Canada, accessed October 2018, at: https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2014006/article/14033-en

4 Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016Lancet. 2017; 390:1211–1259

5 Burden of Migraine Sufferers, MD Analytics, March 2019

6 Emgality Device SF Training Playbook

7 Janet H. Ford, PhD, et al. "Two randomized migraine studies of galcanezumab E?ects on patient functioning and disability."Neurology

8 Holland C. Detke, et al. "Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study."Neurology



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store